1. Home
  2. BMEA vs QUCY Comparison

BMEA vs QUCY Comparison

Compare BMEA & QUCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

N/A

Current Price

$1.96

Market Cap

140.3M

Sector

Health Care

ML Signal

N/A

Logo Mainz Biomed N.V. Ordinary Shares

QUCY

Mainz Biomed N.V. Ordinary Shares

N/A

Current Price

$1.44

Market Cap

114.3M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
BMEA
QUCY
Founded
2017
2008
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
140.3M
114.3M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
BMEA
QUCY
Price
$1.96
$1.44
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$9.83
N/A
AVG Volume (30 Days)
1.8M
818.2K
Earning Date
05-12-2026
06-26-2026
Dividend Yield
N/A
N/A
EPS Growth
69.19
87.68
EPS
N/A
N/A
Revenue
N/A
$537,080.00
Revenue This Year
N/A
$74.34
Revenue Next Year
N/A
$171.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$0.30
52 Week High
$2.99
$4.93

Technical Indicators

Market Signals
Indicator
BMEA
QUCY
Relative Strength Index (RSI) 72.89 50.75
Support Level $1.17 $1.29
Resistance Level $2.00 $1.58
Average True Range (ATR) 0.16 0.13
MACD 0.04 0.01
Stochastic Oscillator 86.18 48.72

Price Performance

Historical Comparison
BMEA
QUCY

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

About QUCY Mainz Biomed N.V. Ordinary Shares

Quantum Cyber NV is focused on building a diversified platform at the intersection of quantum computing and cybersecurity. It aims to secure critical infrastructure and data against these emerging threats.

Share on Social Networks: